Click here to access Zai Lab 2023 Investor Day microsite

 

Corporate Profile

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders to patients in China and around the world. Our goal is to leverage our competencies and resources to positively impact human health worldwide.

INVESTOR HIGHLIGHTS
Corporate Mission

Corporate Mission

Learn More
Investor Presentation

Investor Presentation

Learn More
Our Pipeline

Our Pipeline

Learn More
Stock Quote

2023年 12月 09日 6:52 PM EST

Dec 9, 2023 6:52 PM EST

  • Volume
  • Day Low/High /
  • 52 - Week Low/High /

2023年 12月 09日 6:52 PM EST

Dec 9, 2023 6:52 PM EST

  • Volume
  • Day Low/High /
  • 52 - Week Low/High /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

2023年 12月 09日 6:52 PM EST

Dec 9, 2023 6:52 PM EST

  • Volume
  • Day Low/High /
  • 52 - Week Low/High /

2023年 12月 09日 6:52 PM EST

Dec 9, 2023 6:52 PM EST

  • Volume
  • Day Low/High /
  • 52 - Week Low/High /

Data Provided by Refinitiv. Minimum 15 minutes delayed.


Zai Lab Limited effected a one-to-ten share subdivision effective as of March 30, 2022 (the “Share Subdivision”). Pursuant to the Share Subdivision, each Ordinary Share of the Company was subdivided into ten ordinary shares, and each American Depositary Share (ADS) of the Company now represents ten Ordinary Shares of the Company. If you hold Ordinary Shares of the Company, such as those traded on the Hong Kong Stock Exchange, the number of Ordinary Shares that you held before the Share Subdivision has increased tenfold as a result of the Share Subdivision (therefore if you held 100 Ordinary Shares prior to the Share Subdivision, you now hold 1,000 Ordinary Shares). If you hold ADSs of the Company, such as traded through NASDAQ, the number of ADSs that you held before the Share Subdivision did not change as a result of the Share Subdivision (therefore if you held 100 ADSs prior to the Share Subdivision, you continue to hold 100 ADSs).
Recent Press Releases

Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates

Nov 07, 2023
Read More

Zai Lab Announces Participation in November Investor Conferences

Oct 26, 2023
Read More

Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023

Oct 18, 2023
Read More
More Press Releases

Investor & Media Contacts

Woman looking at phone

Investor Inquiries

Christine Chiou, SVP, Head of Investor Relations
+1 (917) 886-6929
christine.chiou1@zailaboratory.com


Lina Zhang, VP, Corporate Strategy and Capital Markets
lina.zhang@zailaboratory.com

Video Camera

Media Inquiries
Shaun Maccoun, Executive Director, Global Communications
+1 (415) 317-7255
shaun.maccoun@zailaboratory.com
 
Xiaoyu Chen, Executive Director, Regional Communications
xiaoyu.chen@zailaboratory.com
 

Woman looking at laptop